Skip to main content
Top
Published in: Journal of Clinical Immunology 4/2012

01-08-2012

A Novel STAT1 Mutation Associated with Disseminated Mycobacterial Disease

Authors: Elizabeth P. Sampaio, Hannelore I. Bax, Amy P. Hsu, Ervand Kristosturyan, Joseph Pechacek, Prabha Chandrasekaran, Michelle L. Paulson, Dalton L. Dias, Christine Spalding, Gulbu Uzel, Li Ding, Elizabeth McFarland, Steven M. Holland

Published in: Journal of Clinical Immunology | Issue 4/2012

Login to get access

Abstract

STAT1 is a key component of Interferon (IFN)-γ and IFN-α signaling and mediates protection against mycobacteria, fungal, viral infections, and cancer. Dominant negative inhibitory as well as gain of function heterozygous STAT1 mutations demonstrate that IFN-γ driven cellular responses need to be tightly regulated to control infections. We describe an autosomal dominant mutation in the SH2 domain of STAT1 that disrupts protein phosphorylation, c.1961T>A (M654K). The mutant allele does not permit STAT1 phosphorylation, and impairs STAT1 phosphorylation of the wild type allele. Protein dimerization is preserved but DNA binding activity, IFN-γ driven GAS-luciferase activity, and expression of IFN-γ target genes are reduced. IFN-α driven ISRE response, but not IFN-α driven GAS response, are preserved when cells are co-transfected with wild type and the mutant STAT1 constructs. M654K exerts a dominant negative effect on IFN-γ related immunity and is recessive for IFN-α induced immune function.
Literature
1.
go back to reference Wenta N, Strauss H, Meyer S, Vinkemeier U. Tyrosine phosphorylation regulates the partitioning of STAT1 between different dimer conformations. Proc Natl Acad Sci USA. 2008;105:9238–43.PubMedCrossRef Wenta N, Strauss H, Meyer S, Vinkemeier U. Tyrosine phosphorylation regulates the partitioning of STAT1 between different dimer conformations. Proc Natl Acad Sci USA. 2008;105:9238–43.PubMedCrossRef
2.
go back to reference Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu Rev Biochem. 1998;67:227–64.PubMedCrossRef Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu Rev Biochem. 1998;67:227–64.PubMedCrossRef
3.
go back to reference Ho HH, Ivashkiv LB. Role of STAT3 in type I interferon responses. Negative regulation of STAT1-dependent inflammatory gene activation. J Biol Chem. 2006;281:14111–8.PubMedCrossRef Ho HH, Ivashkiv LB. Role of STAT3 in type I interferon responses. Negative regulation of STAT1-dependent inflammatory gene activation. J Biol Chem. 2006;281:14111–8.PubMedCrossRef
4.
go back to reference Averbuch D, Chapgier A, Boisson-Dupuis S, Casanova JL, Engelhard D. The clinical spectrum of patients with deficiency of Signal Transducer and Activator of Transcription1. Pediatr Infect Dis J. 2011;30:352–5.PubMedCrossRef Averbuch D, Chapgier A, Boisson-Dupuis S, Casanova JL, Engelhard D. The clinical spectrum of patients with deficiency of Signal Transducer and Activator of Transcription1. Pediatr Infect Dis J. 2011;30:352–5.PubMedCrossRef
5.
go back to reference Chapgier A, Boisson-Dupuis S, Jouanguy E, Vogt G, Feinberg J, Prochnicka-Chalufour A, et al. Novel STAT1 alleles in otherwise healthy patients with mycobacterial disease. PLoS Genet. 2006;2:e131.PubMedCrossRef Chapgier A, Boisson-Dupuis S, Jouanguy E, Vogt G, Feinberg J, Prochnicka-Chalufour A, et al. Novel STAT1 alleles in otherwise healthy patients with mycobacterial disease. PLoS Genet. 2006;2:e131.PubMedCrossRef
6.
go back to reference Dupuis S, Dargemont C, Fieschi C, Thomassin N, Rosenzweig S, Harris J, et al. Impairment of mycobacterial but not viral immunity by a germline human STAT1 mutation. Science. 2001;293:300–3.PubMedCrossRef Dupuis S, Dargemont C, Fieschi C, Thomassin N, Rosenzweig S, Harris J, et al. Impairment of mycobacterial but not viral immunity by a germline human STAT1 mutation. Science. 2001;293:300–3.PubMedCrossRef
7.
go back to reference Chapgier A, Wynn RF, Jouanguy E, Filipe-Santos O, Zhang S, Feinberg J, et al. Human complete STAT1 deficiency is associated with defective type I and II IFN responses in vitro but immunity to some low virulence viruses in vivo. J Immunol. 2006;176:5078–83.PubMed Chapgier A, Wynn RF, Jouanguy E, Filipe-Santos O, Zhang S, Feinberg J, et al. Human complete STAT1 deficiency is associated with defective type I and II IFN responses in vitro but immunity to some low virulence viruses in vivo. J Immunol. 2006;176:5078–83.PubMed
8.
go back to reference Dupuis S, Jouanguy E, Al-Hajjar S, Fieschi C, Al-Mohsen IZ, Al-Jumaah S, Yang K, et al. Impaired response to interferon-alpha/beta and lethal viral disease in human STAT1 deficiency. Nat Genet. 2003;33:388–91.PubMedCrossRef Dupuis S, Jouanguy E, Al-Hajjar S, Fieschi C, Al-Mohsen IZ, Al-Jumaah S, Yang K, et al. Impaired response to interferon-alpha/beta and lethal viral disease in human STAT1 deficiency. Nat Genet. 2003;33:388–91.PubMedCrossRef
9.
go back to reference Horvath CM, Wen Z, Darnell Jr JE. A STAT protein domain that determines DNA sequence recognition suggests a novel DNA-binding domain. Genes Dev. 1995;15:984–94.CrossRef Horvath CM, Wen Z, Darnell Jr JE. A STAT protein domain that determines DNA sequence recognition suggests a novel DNA-binding domain. Genes Dev. 1995;15:984–94.CrossRef
10.
go back to reference Holland SM, Dorman SE, Kwon A, Pitha-Rowe IF, Frucht DM, Gerstberger SM, et al. Abnormal regulation of interferon-gamma, interleukin-12, and tumor necrosis factor-alpha in human interferon-gamma receptor 1 deficiency. J Infect Dis. 1998;178:1095–104.PubMedCrossRef Holland SM, Dorman SE, Kwon A, Pitha-Rowe IF, Frucht DM, Gerstberger SM, et al. Abnormal regulation of interferon-gamma, interleukin-12, and tumor necrosis factor-alpha in human interferon-gamma receptor 1 deficiency. J Infect Dis. 1998;178:1095–104.PubMedCrossRef
11.
go back to reference Mowen K, David M. Role of the STAT1-SH2 domain and STAT2 in the activation and nuclear translocation of STAT1. J Biol Chem. 1998;273:30073–6.PubMedCrossRef Mowen K, David M. Role of the STAT1-SH2 domain and STAT2 in the activation and nuclear translocation of STAT1. J Biol Chem. 1998;273:30073–6.PubMedCrossRef
12.
go back to reference Renner ED, Rylaarsdam S, Anover-Sombke S, Rack AL, Reichenbach J, et al. Novel signal transducer and activator of transcription 3 (STAT3) mutations, reduced T(H)17 cell numbers, and variably defective STAT3 phosphorylation in hyper-IgE syndrome. J Allergy Clin Immunol. 2008;122:181–7.PubMedCrossRef Renner ED, Rylaarsdam S, Anover-Sombke S, Rack AL, Reichenbach J, et al. Novel signal transducer and activator of transcription 3 (STAT3) mutations, reduced T(H)17 cell numbers, and variably defective STAT3 phosphorylation in hyper-IgE syndrome. J Allergy Clin Immunol. 2008;122:181–7.PubMedCrossRef
13.
go back to reference Qu HQ, Fisher-Hoch SP, McCormick JB. Molecular immunity to mycobacteria: knowledge from the mutation and phenotype spectrum analysis of Mendelian susceptibility to mycobacterial diseases. Int J Infect Dis. 2011;15:e305–13.PubMedCrossRef Qu HQ, Fisher-Hoch SP, McCormick JB. Molecular immunity to mycobacteria: knowledge from the mutation and phenotype spectrum analysis of Mendelian susceptibility to mycobacterial diseases. Int J Infect Dis. 2011;15:e305–13.PubMedCrossRef
14.
go back to reference van de Veerdonk FL, Plantinga TS, Hoischen A, Smeekens SP, Joosten LA, Gilissen C, et al. STAT1 mutations in autosomal dominant chronic mucocutaneous candiasis. N Engl J Med. 2011;365:1806–15. van de Veerdonk FL, Plantinga TS, Hoischen A, Smeekens SP, Joosten LA, Gilissen C, et al. STAT1 mutations in autosomal dominant chronic mucocutaneous candiasis. N Engl J Med. 2011;365:1806–15.
15.
go back to reference Liu L, Okada S, Kong XF, Kreins AY, Cypowyj S, Abhyankar A, et al. Gain-of-function human STAT1mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J Exp Med. 2011;208:1635–48.PubMedCrossRef Liu L, Okada S, Kong XF, Kreins AY, Cypowyj S, Abhyankar A, et al. Gain-of-function human STAT1mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J Exp Med. 2011;208:1635–48.PubMedCrossRef
16.
go back to reference Kong XF, Ciancanelli M, Al-Hajjar S, et al. A novel form of human STAT1 deficiency impairing early but not late responses to interferons. Blood. 2010;116:5895–906.PubMedCrossRef Kong XF, Ciancanelli M, Al-Hajjar S, et al. A novel form of human STAT1 deficiency impairing early but not late responses to interferons. Blood. 2010;116:5895–906.PubMedCrossRef
17.
go back to reference Kristensen IA, Veirum JE, Moller BK, Christiansen M. Novel STAT1 alleles in a patient with impaired resistance to mycobacteria. J Clin Immunol. 2011;31:265–71.PubMedCrossRef Kristensen IA, Veirum JE, Moller BK, Christiansen M. Novel STAT1 alleles in a patient with impaired resistance to mycobacteria. J Clin Immunol. 2011;31:265–71.PubMedCrossRef
18.
go back to reference Chapgier A, Kong XF, Boisson-Dupuis S, Jouanguy E, Averbuch D, Feinberg J, et al. A partial form of recessive STAT1 deficiency in humans. J Clin Invest. 2009;119:1502–14.PubMedCrossRef Chapgier A, Kong XF, Boisson-Dupuis S, Jouanguy E, Averbuch D, Feinberg J, et al. A partial form of recessive STAT1 deficiency in humans. J Clin Invest. 2009;119:1502–14.PubMedCrossRef
19.
go back to reference Vairo D, Tassone L, Tabellini G, Tamassia N, Gasperini S, Bazzoni F, et al. Severe impairment of IFNγ and IFNα responses in cells of a patient with a novel STAT1 splicing mutation. Blood. 2011;118:1806–17.PubMedCrossRef Vairo D, Tassone L, Tabellini G, Tamassia N, Gasperini S, Bazzoni F, et al. Severe impairment of IFNγ and IFNα responses in cells of a patient with a novel STAT1 splicing mutation. Blood. 2011;118:1806–17.PubMedCrossRef
Metadata
Title
A Novel STAT1 Mutation Associated with Disseminated Mycobacterial Disease
Authors
Elizabeth P. Sampaio
Hannelore I. Bax
Amy P. Hsu
Ervand Kristosturyan
Joseph Pechacek
Prabha Chandrasekaran
Michelle L. Paulson
Dalton L. Dias
Christine Spalding
Gulbu Uzel
Li Ding
Elizabeth McFarland
Steven M. Holland
Publication date
01-08-2012
Publisher
Springer US
Published in
Journal of Clinical Immunology / Issue 4/2012
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-012-9659-2

Other articles of this Issue 4/2012

Journal of Clinical Immunology 4/2012 Go to the issue